Nancy U. Lin, MD
Associate Chief, Division of Breast Oncology; Director, Metastatic Breast Cancer Program, Dana-Farber Cancer Institute
Highlights
- Speaker, 2023 Conference on Metastatic Breast Cancer
- Breast medical oncologist focusing on new treatments for people with metastatic breast cancer, with particular interest in brain metastasis
- International leader in clinical research and development of clinical guidelines
- Principal investigator for the Translational Breast Cancer Research Consortium at Dana-Farber
Nancy U. Lin, MD, is the Associate Chief, Division of Breast Oncology and Director of the Metastatic Breast Cancer Program at Dana-Farber Cancer Institute and is an Associate Professor of Medicine at Harvard Medical School. Her research is focused upon developing new treatments for patients with metastatic breast cancer and in understanding mechanisms of therapeutic resistance.
She has led multiple trials of novel systemic approaches for metastatic breast cancer, including patients with breast cancer brain metastases. She has had national and international leadership roles, including serving as the overall principal investigator of several multi-center studies, co-chair of the Response Assessment in Neuro-Oncology metastatic working group, chair of the Friends of Cancer — American Society Modernizing Eligibility Criteria Project — Brain Metastasis Working Group, and membership in national and international guidelines committees for the management of metastatic breast cancer.
Dr. Lin is also experienced in tissue- and blood-based translational research, and with the construction and analysis of clinical databases. She is the principal investigator of the breast oncology-specific tissue banking protocol at Dana-Farber, co-chair of the Dana-Farber/Harvard Clinical Data and Tissue Users’ Committee, and principal investigator of active protocols allowing prospective consent for research biopsies with linked clinical data across all stages of breast cancer, and of the EMBRACE (Ending Metastatic Breast Cancer for Everyone) metastatic cohort study. She serves as the DF/HCC institutional principal investigator for the Translational Breast Cancer Research Consortium.
